Form 4: Ocular Therapeutix Chief Development Officer Sells Shares to Cover Tax Obligations

Ocular Therapeutix's Chief Development Officer, Peter Kaiser, sold 2,897 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Peter Kaiser, Chief Development Officer of Ocular Therapeutix, Inc., sold 2,897 shares of common stock on November 25, 2024.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units on November 22, 2024.
• The shares were sold at a weighted average price of $9.01, with individual transactions ranging from $8.88 to $9.10.
• The sale was not a discretionary trade but rather part of a pre-arranged automatic sale instruction adopted on April 9, 2024.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes and does not indicate any positive or negative sentiment regarding the company's performance or future prospects.

Industry Context

This is a routine transaction for company insiders to manage their tax obligations related to stock-based compensation. It is common for executives to sell shares to cover taxes when restricted stock units vest.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across publicly traded companies.
• The use of pre-arranged automatic sale instructions, such as the one adopted by Peter Kaiser, is a standard method to avoid accusations of insider trading.
• Similar transactions are regularly reported by executives at comparable biotech and pharmaceutical companies.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on the stock price, but it is generally considered a routine event.
• The transaction does not indicate any change in the company's operations or financial health.

Key Dates

Keywords

Ocular Therapeutix, stock sale, insider trading, Form 4, Peter Kaiser, tax obligations, restricted stock units, automatic sale